Skip to content
Motesanib
Motesanib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against vascular endothelial growth factor receptor 2. In addition, it is known to target vascular endothelial growth factor receptor 3 and vascular endothelial growth factor receptor 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
40 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289132——5
Primary myelofibrosisD055728D47.4121——4
Myelodysplastic syndromesD009190D46—21——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8091———10
Breast neoplasmsD001943EFO_0003869C5023———4
Lung neoplasmsD008175C34.9041———4
Multiple myelomaD009101C90.021———3
NeuroblastomaD009447EFO_000062111———2
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A—1———1
Gastrointestinal neoplasmsD005770C26.9—1———1
Thyroid neoplasmsD013964EFO_0003841—1———1
Paraneoplastic syndromesD010257—1———1
Islet cell adenomaD007516EFO_0007331D13.7—1———1
Show 15 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223C85.93————3
Lymphoproliferative disordersD008232Orphanet_2442D47.92————2
Colonic neoplasmsD003110C181————1
Rectal neoplasmsD0120041————1
Pancreatic neoplasmsD010190EFO_0003860C251————1
Esophageal neoplasmsD004938C151————1
Central nervous system neoplasmsD0165431————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMOTESANIB
INNmotesanib
Description
Motesanib is a pyridinecarboxamide.
Classification
Small molecule
Drug classangiogenesis inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Identifiers
PDB3EFL
CAS-ID453562-69-1
RxCUI—
ChEMBL IDCHEMBL572881
ChEBI ID51098
PubChem CID11667893
DrugBankDB05575
UNII IDU1JK633AYI (ChemIDplus, GSRS)
Target
Agency Approved
KDR
KDR
Organism
Homo sapiens
Gene name
KDR
Gene synonyms
FLK1, VEGFR2
NCBI Gene ID
3791
Protein name
vascular endothelial growth factor receptor 2
Protein synonyms
CD309, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, tyrosine kinase growth factor receptor
Uniprot ID
Q14178
Mouse ortholog
Kdr (16542)
vascular endothelial growth factor receptor 2 (Q8VCD0)
Alternate
FLT4
FLT4
FLT1
FLT1
Organism
Homo sapiens
Gene name
FLT4
Gene synonyms
VEGFR3
NCBI Gene ID
2324
Protein name
vascular endothelial growth factor receptor 3
Protein synonyms
Feline McDonough Sarcoma (FMS)-like tyrosine kinase 4, FLT-4, fms related tyrosine kinase 4, Fms-like tyrosine kinase 4, primary congenital lymphedema, Tyrosine-protein kinase receptor FLT4, VEGF receptor-3
Uniprot ID
P35916
Mouse ortholog
Flt4 (14257)
vascular endothelial growth factor receptor 3 (P35917)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 691 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2 adverse events reported
View more details